Adaptimmune Therapeutics PLC: Data from Cohort 1 of SPEARHEA

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel -- Overall response rate

Related Keywords

Pennsylvania , United States , Philadelphia , Vancouver , British Columbia , Canada , America , Briana Van , Julip Miller , Dana Lynch , Sarcoma Foundation Of America , Washington University School Of Medicine , Nasdaq , Exchange Commission , Corporate Communications , Connective Tissue Oncology Society , United Newsfile Corp , Corporate Affairs , Washington University School , Elliot Norry , Chief Medical Officer , Hope Award , Sarcoma Foundation , Specific Peptide Enhanced Affinity Receptor , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Senior Director , Adaptimmune , Herapeutics , Data , Rom , Cohort , Spearhead , Trial , Photos , Ontinue , Support , Submission , Yfami , Synovial , Tarcoma , Response , Gate , Durability , Emain , Consistent ,